Core Points - The company has decided to cancel its supervisory board and increase its registered capital, along with revising its articles of association and governance systems to comply with new regulations [1][3][4] Group 1: Cancellation of Supervisory Board - The company will no longer have a supervisory board or supervisors, with the audit committee of the board taking over the supervisory functions as per the Company Law [1][2] - The relevant rules regarding the supervisory board will be abolished, and corresponding amendments will be made to the articles of association [1][2] Group 2: Increase in Registered Capital - The company has completed the registration of shares for the second vesting period of its 2023 restricted stock incentive plan, resulting in an increase in share capital by RMB 1,457,000 and capital reserve by RMB 13,248,486.43 [3] - The total share capital will change from 135,551,584 shares to 137,008,584 shares, and the registered capital will increase from RMB 135,551,584 to RMB 137,008,584 [3] Group 3: Revision of Articles of Association - The company plans to amend its articles of association to enhance governance structure in line with the new regulations and its strategic development needs [4][5] - The definition of senior management will be adjusted by removing the "Chief Scientist" position, thus changing the definition of senior management to include only the General Manager, Deputy General Managers, Board Secretary, and Financial Officer [4][5] - Numerous amendments will be made to the articles of association, including the uniform change of "Shareholders' Meeting" to "Shareholders' Assembly" and the removal of all references to the supervisory board [5]

Group 1 - Huayang Intelligent's shareholder, Fosun Weiying, plans to reduce its stake by up to 285.42 million shares, representing no more than 5% of the company [1] - Kangtai Biological's controlling shareholder's concerted actor, Du Xinglian, intends to reduce its stake by up to 272.4 million shares, which is no more than 0.24% of the total share capital [2] - Mindray Medical has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [4] Group 2 - Junpu Intelligent's chairman, Liu Yuan, resigned for personal reasons, and Wang Jianfeng was elected as the new chairman [6] - Mingchen Health's actual controller and executives plan to collectively reduce their stake by up to 8.61 million shares, accounting for 3.27% of the total share capital [7] - Zhongheng Design's directors and executives plan to reduce their stake by up to 151.57 million shares, representing no more than 0.55% of the total share capital [9] Group 3 - ST Erya and its actual controller, Zheng Jiping, are still under investigation by the China Securities Regulatory Commission [10] - Qicai Chemical's shareholder, Beijing Fengyan, plans to reduce its stake by up to 399.12 million shares, accounting for 0.98% of the total share capital [11] - Aier Eye Hospital plans to distribute a cash dividend of 0.8 yuan per 10 shares to all shareholders, totaling approximately 744 million yuan [12] Group 4 - Meiri Interactive's actual controller's concerted actor plans to reduce its stake by up to 394.74 million shares, which is 1% of the total share capital [13] - Maipu Medical's pre-IPO shareholder plans to reduce its stake by up to 67.05 million shares, representing no more than 1% of the total share capital [15] - Qinchuan Machine Tool's subsidiary plans to increase its registered capital from 50 million yuan to 200 million yuan, introducing new investors [17] Group 5 - Guiyang Bank's proposed director, Yu Rui, has resigned due to work reasons [19] - Guiyang Bank plans to acquire Xifeng Development Village Bank and establish a branch [20] - Aojing Medical's directors and executives plan to collectively reduce their stake by up to 25.28 million shares, accounting for no more than 0.19% of the total share capital [21] Group 6 - Zhongji Xuchuang intends to issue H-shares and list on the Hong Kong Stock Exchange [22] - ST Huatuo's stock will have its risk warning lifted, changing its name to Shiji Huatuo [25] - *ST Gaohong's stock has been delisted from the Shenzhen Stock Exchange [27] Group 7 - Tianwo Technology plans to publicly transfer a 7.12% stake in Qinghai Haihe Railway Transportation Co., with an assessed value of approximately 8.54 million yuan [28] - Xingye Technology's major shareholder plans to reduce its stake by up to 886.65 million shares, representing no more than 3% of the total share capital [29] - Jiangnan Chemical has successfully acquired 100% equity of Chongqing Shun'an Explosive Materials Co., with a transfer base price of 1 billion yuan [31]

Summary of Key Points Core Viewpoint - On November 10, several A-share listed companies disclosed their shareholding changes, with some announcing share buybacks while others reported share reductions by major shareholders [1]. Group 1: Share Buybacks - Hangcai Co. proposed to use 50 million to 100 million yuan of surplus funds for share repurchase [2]. - Sunong Bank executives plan to increase their holdings by no less than 1.8 million yuan in A-shares within six months [2]. - Jiangsu Cable's controlling shareholder received loan support for increasing A-share holdings [2]. Group 2: Share Reductions - A total of 25 A-share listed companies announced share reductions, including: - Aojing Medical plans to reduce no more than 0.19% of its shares by directors and executives [2]. - Maipu Medical's shareholder Guoshou Chengda intends to reduce no more than 1% of its shares [2]. - Shoulv Hotel's Ctrip Shanghai reduced 25.206 million shares on November 10 [2]. - Mingchen Health's controlling shareholder plans to reduce no more than 3% of the total share capital [2]. - Meiri Interactive's shareholder "I Got a Push" intends to reduce no more than 1% of its shares [2]. - Qicai Chemical's shareholder Beijing Fengyan plans to reduce no more than 0.98% of its shares [2]. - Other companies with planned reductions include Zhongheng Design, Xin Kaipu, Lianying Laser, Hongxin Electronics, and others, with reductions ranging from 0.07% to 5% [2].

Core Points - The company announced the nomination of candidates for its third board of directors, including both non-independent and independent directors [2] Group 1: Board of Directors Nominations - The board of directors has approved the nomination of Huang Wanlan, Qiu Zhiye, Song Tianxi, Tian Guofeng, and Liu Yang as non-independent director candidates [2] - The board has also approved the nomination of Su Jian, Li Xiaoming, and Zhao Lingyun as independent director candidates, with Su Jian being a professional accountant [2]

Core Viewpoint - The company, Aojing Medical (688613.SH), announced plans for share reduction by key executives due to personal funding needs, which may impact investor sentiment and stock performance [1] Summary by Relevant Sections Share Reduction Plans - The company's general manager, Mr. Qiu Zhiye, plans to reduce his holdings by up to 95,000 shares, representing no more than 0.07% of the total share capital [1] - The financial officer, Ms. Wang Ling, intends to reduce her holdings by up to 70,312 shares, accounting for no more than 0.05% of the total share capital [1] - Vice general managers, Mr. Song Tianxi and Mr. Tian Guofeng, plan to reduce their holdings by up to 50,000 shares (0.04%) and 37,500 shares (0.03%) respectively [1] Implementation Timeline - The reduction plans will be executed within three months starting from 15 trading days after the announcement [1] - The total number of shares reduced through centralized bidding will not exceed 1% of the company's total shares over any continuous 90-day period [1] Adjustments and Pricing - Any changes in share capital due to stock dividends, capital reserve transfers, or other share changes will lead to corresponding adjustments in the planned reduction amounts [1] - The reduction price will be determined based on market prices and the method of transaction [1]

证券代码：688613 证券简称：奥精医疗 公告编号：2025-061 奥精医疗科技股份有限公司 董事及高级管理人员减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 董事及高级管理人员持股的基本情况 截至本公告披露日，奥精医疗科技股份有限公司（以下简称"公司 "）本次 拟减持的董事及高级管理人员持股情况如下： 公司董事、总经理仇志烨先生持有公司股份 380000 股，占公司总股本的比 例为 0.28%；公司财务负责人、高级管理人员王玲女士持有公司股份 281250 股， 占公司总股本的比例为 0.21%；公司董事、副总经理宋天喜先生持有公司股份 200000 股，占公司总股本的比例为 0.15%；公司董事、副总经理田国峰先生持 有公司股份 150000 股，占公司总股本的比例为 0.11%；上述股份来源为股权激 励取得，均为无限售条件流通股。 减持计划的主要内容 因自身资金需求，公司董事、总经理仇志烨先生，公司财务负责人、高级管 理人员王玲女士，公司董事、副总经理宋天喜先生，公司 ...

Core Viewpoint - The company, Aojing Medical (688613.SH), announced plans for share reduction by key executives due to personal funding needs, which may impact investor sentiment and stock performance [1] Summary by Relevant Sections Share Reduction Plans - The company's general manager, Mr. Qiu Zhiye, plans to reduce his holdings by up to 95,000 shares, representing no more than 0.07% of the total share capital [1] - The financial officer, Ms. Wang Ling, intends to reduce her holdings by up to 70,312 shares, accounting for no more than 0.05% of the total share capital [1] - Vice general managers, Mr. Song Tianxi and Mr. Tian Guofeng, plan to reduce their holdings by up to 50,000 shares (0.04%) and 37,500 shares (0.03%), respectively [1] Implementation Timeline - The reduction plans will be executed within three months starting from 15 trading days after the announcement [1] - The total number of shares reduced through centralized bidding will not exceed 1% of the company's total shares over any continuous 90-day period [1] Adjustments and Pricing - Any changes in share capital due to stock dividends, capital reserve transfers, or other corporate actions will lead to corresponding adjustments in the planned reduction amounts [1] - The reduction price will be determined based on market conditions and the method of transaction [1]

Core Viewpoint - Aozheng Medical (688613.SH) announced that several key executives plan to reduce their shareholdings due to personal funding needs [1] Group 1: Shareholding Reduction Details - CEO Qiu Zhiye plans to reduce his holdings by up to 95,000 shares, representing no more than 0.07% of the company's total share capital [1] - Financial officer Wang Ling intends to reduce her holdings by up to 70,312 shares, accounting for no more than 0.05% of the total share capital [1] - Vice President Song Tianxi aims to reduce his holdings by up to 50,000 shares, which is no more than 0.04% of the total share capital [1] - Vice President Tian Guofeng plans to reduce his holdings by up to 37,500 shares, representing no more than 0.03% of the total share capital [1]

Core Viewpoint - The announcement from Aojing Medical (688613.SH) indicates that several key executives plan to reduce their shareholdings in the company due to personal funding needs [1] Summary by Relevant Categories Shareholding Reduction - CEO Qiu Zhiye plans to reduce his holdings by no more than 95,000 shares, representing up to 0.07% of the total share capital [1] - Financial officer Wang Ling intends to reduce her holdings by no more than 70,312 shares, accounting for up to 0.05% of the total share capital [1] - Vice President Song Tianxi aims to reduce his holdings by no more than 50,000 shares, which is up to 0.04% of the total share capital [1] - Vice President Tian Guofeng plans to reduce his holdings by no more than 37,500 shares, representing up to 0.03% of the total share capital [1]

Core Viewpoint - The company, AoJing Medical (688613), announced plans for share reductions by several key executives, indicating potential changes in insider ownership and market sentiment [1] Group 1: Share Reduction Plans - The company's general manager, Qiu Zhiye, plans to reduce holdings by up to 95,000 shares [1] - The financial officer and senior manager, Wang Ling, intends to reduce holdings by up to 70,300 shares [1] - The company's vice general managers, Song Tianxi and Tian Guofeng, plan to reduce holdings by up to 50,000 shares and 37,500 shares, respectively [1] - The total shares to be reduced by these executives amount to no more than 0.19% of the company's total share capital [1]